Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug

Advanced Drug Delivery Reviews

Volumn 59, Issue 6, 2007, Pages 419-426

  Hanafy, A ^a   Spahn Langguth, H ^b   Vergnault, G ^c   Grenier, P ^c   Tubic Grozdanis, M ^d   Lenhardt, T ^d   Langguth, P ^d  

^a Kafrelsheikh University   (Egypt)

^b GERMAN UNIVERSITY IN CAIRO   (Egypt)

^c SkyePharma AG   (Switzerland)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Absorption; Bioavailability enhancement; Nanomedicine; Nanosuspension; Nanotechnology; Oral drug delivery; Rat

Indexed keywords

ABSORPTION; LIPIDS; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PHARMACOKINETICS; SALINE WATER; SOLUBILITY; SUSPENSIONS (FLUIDS);

BIOAVAILABILITY ENHANCEMENT; ORAL DRUG DELIVERY; PHYSIOLOGICAL SALINE;

DRUG DELIVERY;

FENOFIBRATE; HYDROXYETHYLCELLULOSE; SOLID LIPID NANOPARTICLE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG HALF LIFE; DRUG SOLUBILITY; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; REVIEW; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; ANTILIPEMIC AGENTS; BIOLOGICAL AVAILABILITY; COMPUTER SIMULATION; LIPIDS; MALE; MODELS, BIOLOGICAL; NANOPARTICLES; PROCETOFEN; RATS; RATS, WISTAR; SOLUBILITY; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 34547863131     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.04.005     Document Type: Review

References (19)

1. Rao G.C., Kumar M.S., Mathivanan N., and Rao M.E. Nanosuspensions as the most promising approach in nanoparticulate drug delivery systems. Pharmazie 59 (2004) 5-9
2. G.G. Liversidge, K.C. Cundy, J. Bishop, D. Czekai, Surface modified drug nanoparticles United States Patent No. 5145684 (1991).
3. Liversidge G.G., and Cundy K.C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailabilty of nanocrystalline danazol in beagel dogs. Int. J. Pharm. 125 (1995) 91-97
4. Jinno J., Kamada N., Miyake M., Yamada K., Mukai T., Odomi M., Toguchi H., Liversidge G.G., Higaki K., and Kimura T. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J. Control. Release 111 (2006) 56-64
5. R.H. Müller, R. Becker, B. Kruss, K. Peters, Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution United States Patent No. 5858410 (1998).
6. Langguth P., Hanafy A., Frenzel D., Grenier P., Nhamias A., Ohlig T., Vergnault G., and Spahn-Langguth H. Nanosuspension formulations for low-soluble drugs: pharmacokinetic evaluation using spironolactone as model compound. Drug Dev. Ind. Pharm. 31 (2005) 319-329
7. Dollery C. Therapeutic Drugs. 2nd ed. (1999)
8. Weil A., Caldwell J., and Strolin-Benedetti M. The metabolism and disposition of fenofibrate in rat, guinea pig, and dog. Drug Metab. Dispos. 16 (1988) 302-309
9. Shepherd J. The fibrates in clinical practice: focus on micronised fenofibrate. Atherosclerosis 110 (1994) S55-S63 (Suppl)
10. Mathur L.K., and Wickman A. Stability of extemporaneously compounded spironolactone suspensions. Am. J. Hosp. Pharm. 46 (1989) 2040-2042
11. Nahata M.C., Morosco R.S., and Hipple T.F. Stability of spironolactone in an extemporaneously prepared suspension at two temperatures. Ann. Pharmacother. 27 (1993) 1198-1199
12. W.R., Heinzel G., and Thomann P. TopFit: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC (1993), Gustav-Fischer-Verlag, Stuttgart
13. Kommentar zum Europäischen Arzneibuch. Vol. 5; D-H. 2006, Stuttgart, Eschborn: Wissenschaftliche Verlagsgesellschaft mgH, Govi Verlag. 4.00/1322.
14. Granero G.E., Ramachandran C., and Amidon G.L. Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. Drug Dev. Ind. Pharm. 31 (2005) 917-922
15. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 Suppl 2 (2000) S73-S80
16. Noyes A.A., and Whitney W.R. The rate of solution of solid substances in their own solutions. J. Am. Chem. Soc. 19 (1897) 930-934
17. Dintaman J.M., and Silverman J.A. Inhibition of P-glycoprotein by d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm. Res. 16 (1999) 1550-1556
18. Wu C.Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
19. Brittain H.G. In: Swarbrick J. (Ed). Physical Characterization of Pharmaceutical Solids. Drugs and Pharmaceutical Sciences vol. 70 (1995), Marcel Dekker, New York 327-329